journal article·2024-12Open access

Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies

Eunseo Choi, Alexander Bagley, Sakib Haque, Celeste Winters, Conroy Sun

Abstract

Intratumoral delivery of cytotoxic or immunomodulating compounds is a promising approach for cancer therapy. When a primary tumor or its metastases can be accessed through minimally invasive or conventional surgery, the direct administration of therapeutic agents may serve to not only eradicate local tumors but also reduce systemic tumor burden. Currently, numerous conventional and novel agents are under investigation as intratumoral-based therapies, including immunomodulators that target specific biological pathways and nanomaterials such as high-Z nanoparticle radiosensitizers. While the shift from systemic to intratumoral therapy has been actively investigated in preclinical and clinical research, the adoption of intratumoral drug delivery remains unclear, necessitating the development of new techniques to validate the feasibility and safety of this delivery route. Here, we review and assess recent advances in immunotherapy in terms of biomaterials and delivery platform development and discuss clinically relevant imaging technologies for guiding intratumoral delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Cancer immunotherapy, Part 3: challenges and future trends
2. Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment10.1016/j.apsb.2020.09.014 ↗
3. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)10.1093/annonc/mdy423 ↗
4. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: report of first patient experience
5. Clinical and preclinical outcomes of combining targeted therapy with radiotherapy10.3389/fonc.2021.749496 ↗
6. Systemic effects of local radiotherapy10.1016/S1470-2045(09)70082-8 ↗
7. Application of radiosensitizers in cancer radiotherapy10.2147/IJN.S290438 ↗
8. Using immunotherapy to boost the abscopal effect10.1038/nrc.2018.6 ↗
9. The abscopal effect of radiation therapy10.2217/fon-2020-0994 ↗
10. Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies10.1016/j.rpor.2018.11.001 ↗
11. Solutions to the drawbacks of photothermal and photodynamic cancer therapy10.1002/advs.202002504 ↗
12. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy10.1038/s41401-020-0400-z ↗
13. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
14. Chemodynamic therapy: tumour microenvironment-mediated Fenton and fenton-like reactions10.1002/anie.201805664 ↗
15. Immunogenic death of colon cancer cells treated with oxaliplatin10.1038/onc.2009.356 ↗
16. Boosting the immune response-combining local and immune therapy for prostate cancer treatment10.3390/cells11182793 ↗
17. The role of biomarkers in personalized immunotherapy10.1186/s40364-022-00378-0 ↗
18. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma10.1186/s12931-023-02443-0 ↗
19. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity10.1186/s13045-020-00946-7 ↗
20. Programmed cell death pathways in hearing loss: a review of apoptosis, autophagy and programmed necrosis10.1111/cpr.12915 ↗
21. Targeting apoptosis in cancer therapy10.1038/s41571-020-0341-y ↗
22. Immunogenic cell death in cancer therapy: present and emerging inducers10.1111/jcmm.14356 ↗
23. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma10.1136/jitc-2019-000282 ↗
24. Immunogenic effects of chemotherapy-induced tumor cell death10.1016/j.gendis.2018.05.003 ↗
25. New anti-cancer explorations based on metal ions10.1186/s12951-022-01661-w ↗
26. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance10.1186/s12943-022-01530-y ↗
27. Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging
28. Targeting ferroptosis opens new avenues for the development of novel therapeutics10.1038/s41392-023-01606-1 ↗
29. Pyroptosis: host cell death and inflammation10.1038/nrmicro2070 ↗
30. The therapeutic potential of pyroptosis in melanoma10.3390/ijms24021285 ↗
31. Immunology of cell death in cancer immunotherapy10.3390/cells10051208 ↗
32. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications10.1038/s41423-020-0488-6 ↗
33. Type I interferons and dendritic cells in cancer immunotherapy10.1016/bs.ircmb.2019.06.001 ↗
34. 'Toll' gates for future immunotherapy10.2174/138161206778743484 ↗
35. Toll-like receptors and innate immunity10.1038/35100529 ↗
36. Toll-like receptor-targeted anti-tumor therapies: advances and challenges10.3389/fimmu.2022.1049340 ↗
37. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists10.1038/nm1589 ↗
38. TLR agonists: our best frenemy in cancer immunotherapy10.1189/jlb.1012501 ↗
39. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system10.1586/ecp.11.5 ↗
40. Intratumoral immunotherapy for early-stage solid tumors10.1158/1078-0432.CCR-19-3642 ↗
41. STING: a master regulator in the cancer-immunity cycle10.1186/s12943-019-1087-y ↗
42. cGAS-STING, an important pathway in cancer immunotherapy10.1186/s13045-020-00916-z ↗
43. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy10.1021/acs.chemrev.1c00750 ↗
44. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model
45. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy10.1038/s41565-018-0342-5 ↗
46. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity10.1016/j.celrep.2018.11.047 ↗
47. Cytokines in the treatment of cancer10.1089/jir.2018.0019 ↗
48. Cytokines in clinical cancer immunotherapy10.1038/s41416-018-0328-y ↗
49. Engineering interferons and interleukins for cancer immunotherapy10.1016/j.addr.2022.114112 ↗
50. IL-12 family cytokines in cancer and immunotherapy10.3390/cancers13020167 ↗
51. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity10.1038/s41551-021-00831-9 ↗
52. Cytokine conjugation to enhance T cell therapy10.1073/pnas.2213222120 ↗
53. Activation of adaptive and innate immune cells via localized IL2 cytokine factories eradicates mesothelioma tumors10.1158/1078-0432.CCR-22-1493 ↗
54. Oncolytic virotherapy: basic principles, recent advances and future directions10.1038/s41392-023-01407-6 ↗
55. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses10.1038/mtm.2016.18 ↗
56. Strategies to develop potent oncolytic viruses and enhance their therapeutic efficacy
57. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective10.3390/v15081645 ↗
58. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies10.1016/j.it.2017.11.006 ↗
59. Intratumoral delivery of interleukin 9 via oncolytic vaccinia virus elicits potent antitumor effects in tumor models10.3390/cancers16051021 ↗
60. Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide
61. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters10.3389/fonc.2020.605380 ↗
62. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects10.1038/s41392-019-0089-y ↗
63. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges10.1177/1535676019899502 ↗
64. Non viral vectors in gene therapy- an overview
65. Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect10.1016/j.omtn.2018.04.003 ↗
66. Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer10.1038/s41417-019-0137-3 ↗
67. Transcriptional targeting in cancer gene therapy
68. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment10.1158/1078-0432.CCR-20-0472 ↗
69. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs10.1126/scitranslmed.aat9143 ↗
70. Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells10.1016/j.ccell.2019.10.006 ↗
71. Intratumoral drug delivery with nanoparticulate carriers10.1007/s11095-010-0360-y ↗
72. Metallic nanoparticles for cancer immunotherapy10.1016/j.mattod.2017.11.022 ↗
73. A review of clinical translation of inorganic nanoparticles10.1208/s12248-015-9780-2 ↗
74. Lanthanides: applications in cancer diagnosis and therapy10.1021/acs.jmedchem.5b01975 ↗
75. Metal-organic frameworks for biomedical applications10.1002/smll.201906846 ↗
76. Metal-organic frameworks (MOFs) for cancer therapy10.3390/ma14237277 ↗
77. Nanoscale metal-organic frameworks generate reactive oxygen species for cancer therapy10.1021/acscentsci.0c00397 ↗
78. Lanthanide-based MOFs: synthesis approaches and applications in cancer diagnosis and therapy10.1039/D2TB01884E ↗
79. Nanoscale hafnium metal-organic frameworks enhance radiotherapeutic effects by upregulation of type I interferon and TLR7 expression
80. Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials
81. Delivery of nanoparticle-based radiosensitizers for radiotherapy applications10.3390/ijms21010273 ↗
82. Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists10.1186/s12951-022-01477-8 ↗
83. Toll-like receptor agonist conjugation: a chemical perspective10.1021/acs.bioconjchem.7b00808 ↗
84. Chemical strategies to enhance the therapeutic efficacy of toll-like receptor agonist based cancer immunotherapy10.1021/acs.accounts.0c00337 ↗
85. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity10.1038/s41563-022-01251-z ↗
86. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy10.1073/pnas.1916039117 ↗
87. Synthesis and characterization of PEGylated toll like receptor 7 ligands10.1021/bc1004813 ↗
88. Modulating the innate immune response by combinatorial engineering of endotoxin10.1073/pnas.1218080110 ↗
89. Lipid A modification systems in gram-negative bacteria10.1146/annurev.biochem.76.010307.145803 ↗
90. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action10.1038/s41570-020-00244-3 ↗
91. Engineered immunogen binding to alum adjuvant enhances humoral immunity10.1038/s41591-020-0753-3 ↗
92. Nanoparticle mediated cancer immunotherapy10.1016/j.semcancer.2020.03.015 ↗
93. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA10.1016/j.jconrel.2022.03.020 ↗
94. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens10.1038/s41587-019-0390-x ↗
95. In situ cancer vaccination using lipidoid nanoparticles10.1126/sciadv.abf1244 ↗
96. National Cancer Institute (NCI) state of the science: targeted radiosensitizers in colorectal cancer10.1002/cncr.32150 ↗
97. Systemic benefit of radiation therapy via abscopal effect10.3389/fonc.2022.987142 ↗
98. Self-guiding polymeric prodrug micelles with two aggregation-induced emission photosensitizers for enhanced chemo-photodynamic therapy10.1021/acsnano.0c09407 ↗
99. Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics10.7150/thno.5284 ↗
100. Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy10.1016/j.jphotobiol.2013.11.007 ↗